Literature DB >> 19671625

Does the estradiol level on the day of human chorionic gonadotrophin administration have an impact on pregnancy rates in patients treated with rec-FSH/GnRH antagonist?

D Kyrou1, B Popovic-Todorovic, H M Fatemi, C Bourgain, P Haentjens, L Van Landuyt, P Devroey.   

Abstract

BACKGROUND: The purpose of this prospective observational study was to evaluate the association between estradiol (E(2)) levels on the day of human chorionic gonadotrophin (hCG) administration and pregnancy rates in a recombinant FSH (rec-FSH) antagonist fixed protocol.
METHODS: A group of 207 patients (<or=39 years of age), treated by IVF/ICSI, received 200 IU/day rec-FSH from Day 2 of the cycle and daily GnRH antagonist starting on Day 6 of stimulation. The criteria for hCG administration included only the presence of >or=3 follicles of >or=17 mm diameter. One to two embryos were transferred on Day 3 after oocyte retrieval.
RESULTS: The area under the curve (AUC) for E(2) on the day of hCG could not distinguish between pregnant and non-pregnant women (AUC:0.5; 95% confidence interval (CI): 0.42-0.59). No significant difference was observed between the three percentile groups of E(2) values on the day of hCG administration [group 1, lower 25th percentile (<1142 pg/ml); group 2, medium 50th percentile (1142-2446 pg/ml) and group 3, higher 75th percentile (>2446 pg/ml)] for the ongoing pregnancy rates (P = 0.52). On the contrary, the linear regression model showed that higher E(2) values on the day of hCG administration significantly improved the scores of transferred embryos (P = 0.01) as well as the total embryo score (P = 0.02). Yet subgroup analysis only in this high responders group revealed lower E(2) and progesterone levels on the day of hCG in pregnant women compared with the non-pregnant (P = 0.01).
CONCLUSIONS: E(2) concentrations on the day of hCG administration in GnRH antagonist cycles are not associated with pregnancy rates. A potential deleterious impact of estradiol on endometrial receptivity is shown for the high responders who have high E(2) levels and improved embryo quality without a concomitant rise in pregnancy rate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671625     DOI: 10.1093/humrep/dep290

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  30 in total

1.  Different ART outcomes at increasing peak estradiol levels with long and antagonist protocols: retrospective insights from ten years experience.

Authors:  Massimo Manno; Marta Cervi; Donatella Zadro; Giuseppa Fuggetta; Valter Adamo; Francesco Tomei
Journal:  J Assist Reprod Genet       Date:  2011-04-26       Impact factor: 3.412

2.  Serum estradiol as a predictor of success of in vitro fertilization.

Authors:  Suneeta Mittal; Prerna Gupta; Neena Malhotra; Neeta Singh
Journal:  J Obstet Gynaecol India       Date:  2013-11-01

3.  Clinical and genetic analysis of cytochrome P450 oxidoreductase (POR) deficiency in a female and the analysis of a novel POR intron mutation causing alternative mRNA splicing : Overall analysis of a female with POR deficiency.

Authors:  Tao Zhang; Zhou Li; Xinling Ren; Bo Huang; Guijin Zhu; Wei Yang; Lei Jin
Journal:  J Assist Reprod Genet       Date:  2020-07-28       Impact factor: 3.412

4.  Effect of infertility treatment and pregnancy-related hormones on breast cell proliferation in vitro.

Authors:  Anne Cooley; Laura Matthews; Stanislav Zelivianski; Ashley Hardy; Jacqueline S Jeruss
Journal:  Hum Reprod       Date:  2011-11-10       Impact factor: 6.918

5.  Is the probability of pregnancy after ovarian stimulation for IVF associated with serum estradiol levels on the day of triggering final oocyte maturation with hCG? A systematic review and meta-analysis.

Authors:  Glykeria I Karatasiou; J K Bosdou; C A Venetis; L Zepiridis; K Chatzimeletiou; T B Tarlatzi; G Lainas; B C Tarlatzis; G Grimbizis; E M Kolibianakis
Journal:  J Assist Reprod Genet       Date:  2020-05-29       Impact factor: 3.412

6.  A decrease in serum estradiol levels after human chorionic gonadotrophin administration predicts significantly lower clinical pregnancy and live birth rates in in vitro fertilization cycles.

Authors:  L A Kondapalli; T A Molinaro; M D Sammel; A Dokras
Journal:  Hum Reprod       Date:  2012-06-29       Impact factor: 6.918

Review 7.  Why we should transfer frozen instead of fresh embryos: the translational rationale.

Authors:  Rachel Weinerman; Monica Mainigi
Journal:  Fertil Steril       Date:  2014-06-02       Impact factor: 7.329

8.  Association Between Serum Estradiol Level on the Day of hCG Administration and IVF-ICSI Outcome.

Authors:  Fatemeh Foroozanfard; Seyed Alireza Moraveji; Seyed Abdolvahab Taghavi; Fatemeh Karimi
Journal:  J Obstet Gynaecol India       Date:  2015-03-22

Review 9.  Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017).

Authors:  Human Fatemi; Wilma Bilger; Deborah Denis; Georg Griesinger; Antonio La Marca; Salvatore Longobardi; Mary Mahony; Xiaoyan Yin; Thomas D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2021-05-11       Impact factor: 5.211

10.  Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial.

Authors:  Arthur Leader; Paul Devroey; Han Witjes; Keith Gordon
Journal:  Reprod Biol Endocrinol       Date:  2013-06-11       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.